Nauru vs Zimbabwe: Death rate from cancer
Nauru
76.41 deaths per 100,000 people
in 2021
Zimbabwe
76.23 deaths per 100,000 people
in 2021
Nauru rank
112th
Zimbabwe rank
113th
Death rate from cancer over time
- Nauru
- Zimbabwe
How they compare
Nauru currently reports 76.41 deaths per 100,000 people against 76.23 deaths per 100,000 people in Zimbabwe, a difference of 0.18 deaths per 100,000 people.
The two have swapped places 1 time across 22 shared years of data; in 2000 it was Zimbabwe ahead.
Nauru ranks 112th and Zimbabwe ranks 113th of 194 countries.
Zimbabwe has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Nauru | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 68.45 deaths per 100,000 people | 101.63 deaths per 100,000 people | 33.19 deaths per 100,000 people | Zimbabwe |
| 2010s | 68.29 deaths per 100,000 people | 108.71 deaths per 100,000 people | 40.43 deaths per 100,000 people | Zimbabwe |
| 2020s | 73.2 deaths per 100,000 people | 86.38 deaths per 100,000 people | 13.17 deaths per 100,000 people | Zimbabwe |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from cancer, Nauru or Zimbabwe?
- Nauru, at 76.41 deaths per 100,000 people against 76.23 deaths per 100,000 people in Zimbabwe as of 2021.
- What is the difference in death rate from cancer between Nauru and Zimbabwe?
- 0.18 deaths per 100,000 people, with Nauru ahead.
- How many years of comparable data are there for Nauru and Zimbabwe?
- 22 years are reported by both, from 2000 to 2021.
- How do Nauru and Zimbabwe rank globally for death rate from cancer?
- Nauru ranks 112th and Zimbabwe ranks 113th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Death rate from cancer. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from malignant neoplasms in both sexes, per 100,000 people.